OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
Clinical Trials
467
Active:9
Completed:288
Trial Phases
5 Phases
Phase 1:83
Phase 2:111
Phase 3:150
+2 more phases
Drug Approvals
84
CANADA:30
NMPA:14
SFDA:8
+2 more agencies
Drug Approvals
Aripiprazole for Injection
- Product Name
- 注射用阿立哌唑
- Approval Number
- 国药准字HJ20230054
- Approval Date
- Dec 18, 2023
NMPA
Aripiprazole for Injection
- Product Name
- 注射用阿立哌唑
- Approval Number
- 国药准字HJ20230055
- Approval Date
- Dec 18, 2023
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (434 trials with phase data)• Click on a phase to view related trials
Phase 3
150 (34.6%)Phase 2
111 (25.6%)Phase 1
83 (19.1%)Not Applicable
57 (13.1%)Phase 4
21 (4.8%)phase_2_3
10 (2.3%)phase_1_2
2 (0.5%)A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
Not Applicable
Recruiting
- Conditions
- Attention-Deficit Hyperactivity Disorder(ADHD)
- Interventions
- Drug: EB-1020 (Centanafadine) low doseDrug: EB-1020 (Centanafadine) high dose
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT07087327
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Japan
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
Not Applicable
Recruiting
- Conditions
- Attention-Deficit Hyperactivity Disorder(ADHD)
- Interventions
- Drug: EB-1020 (Centanafadine) low doseDrug: EB-1020 (Centanafadine) high doseDrug: Placebo
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 315
- Registration Number
- NCT07086313
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Japan
LUPKYNIS Drug-use Results Survey
Recruiting
- Conditions
- Lupus Nephritis
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT07053891
- Locations
- 🇯🇵
Pharmacovigilance Department, Osaka, Japan
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
Phase 2
Recruiting
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: EB-1020 (Centanafadine) 164.4 mgDrug: EB-1020 (Centanafadine) 328.8 mgDrug: Placebo
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 630
- Registration Number
- NCT06931080
- Locations
- 🇯🇵
Maynds Tower Mental Clinic, Tokyo, Japan
A Long-term Trial of EB-1020 in Adult Patients With ADHD
Phase 3
Recruiting
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: EB-1020 (Centanafadine) 164.4 mgDrug: EB-1020 (Centanafadine) 328.8 mg
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06926829
- Locations
- 🇯🇵
Maynds Tower Mental Clinic, Tokyo, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 29
- Next
News
Difamilast Shows Comparable Efficacy and Safety to Delgocitinib in Atopic Dermatitis: A Matching-Adjusted Indirect Comparison
A matching-adjusted indirect comparison (MAIC) study suggests difamilast 1% cream has comparable efficacy and safety to delgocitinib in treating moderate-to-severe atopic dermatitis (AD).